share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  10/22 05:21

牛牛AI助理已提取核心訊息

180 Life Sciences Corp. has successfully completed a warrant inducement agreement with a holder of its existing warrants, resulting in the full exercise of warrants for cash and the issuance of new unregistered warrants. The agreement, initially reported on October 16, 2024, led to the holder exercising existing warrants to purchase 950,069 shares of common stock at $3.48 per share on October 16 and 17, 2024. This transaction provided the company with $3,306,240 before expenses. In return, the company issued new warrants to the holder to purchase double the number of shares acquired through the existing warrants at an exercise price of $1.50 per share, exercisable immediately and valid for five years. The issuance of these new warrants is exempt from registration under the Securities Act. The company corrected previous errors in reporting, adjusting the number of shares and the total funds raised from the exercise of the existing warrants. The corrected figures are 950,069 shares and $3,306,240, respectively.
180 Life Sciences Corp. has successfully completed a warrant inducement agreement with a holder of its existing warrants, resulting in the full exercise of warrants for cash and the issuance of new unregistered warrants. The agreement, initially reported on October 16, 2024, led to the holder exercising existing warrants to purchase 950,069 shares of common stock at $3.48 per share on October 16 and 17, 2024. This transaction provided the company with $3,306,240 before expenses. In return, the company issued new warrants to the holder to purchase double the number of shares acquired through the existing warrants at an exercise price of $1.50 per share, exercisable immediately and valid for five years. The issuance of these new warrants is exempt from registration under the Securities Act. The company corrected previous errors in reporting, adjusting the number of shares and the total funds raised from the exercise of the existing warrants. The corrected figures are 950,069 shares and $3,306,240, respectively.
180 Life Sciences Corp.已成功完成與現有持有人的權證誘導協議,導致全部現金行權併發行新的未註冊權證。該協議最初於2024年10月16日報告,導致持有人在2024年10月16日和17日行使現有權證,以每股3.48美元的價格購買950,069股普通股。該交易爲公司帶來了3,306,240美元,扣除費用。作爲回報,公司向持有人發行新的權證,以1.50美元的行權價格購買雙倍於通過現有權證獲得的股票數量,立即可行使,有效期五年。這些新權證的發行不受《證券法》登記要求的限制。公司糾正了之前的報告錯誤,調整了通過行使現有權證所獲股票數量和總募集資金。正確的數字分別爲950,069股和3,306,240美元。
180 Life Sciences Corp.已成功完成與現有持有人的權證誘導協議,導致全部現金行權併發行新的未註冊權證。該協議最初於2024年10月16日報告,導致持有人在2024年10月16日和17日行使現有權證,以每股3.48美元的價格購買950,069股普通股。該交易爲公司帶來了3,306,240美元,扣除費用。作爲回報,公司向持有人發行新的權證,以1.50美元的行權價格購買雙倍於通過現有權證獲得的股票數量,立即可行使,有效期五年。這些新權證的發行不受《證券法》登記要求的限制。公司糾正了之前的報告錯誤,調整了通過行使現有權證所獲股票數量和總募集資金。正確的數字分別爲950,069股和3,306,240美元。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。